{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T17:09:37Z","timestamp":1765904977910,"version":"3.48.0"},"reference-count":0,"publisher":"Tunisian Society of Medical Sciences","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tunis Med"],"abstract":"<jats:p>Introduction : Le suivi th\u00e9rapeutique pharmacologique (STP) de l\u2019acide valpro\u00efque (VPA) chez les enfants \u00e9pileptiques permet d\u2019optimiser le traitement afin de favoriser le contr\u00f4le des crises et de d\u00e9tecter les enfants r\u00e9fractaires qui devraient \u00eatre pris en charge pr\u00e9cocement. Le but de notre travail \u00e9tait d\u2019identifier un effet seuil de dose et\/ou de concentration du VPA chez des enfants \u00e9pileptiques en r\u00e9mission.\nM\u00e9thodes : Cette \u00e9tude r\u00e9trospective a \u00e9t\u00e9 men\u00e9e en Pharmacologie Clinique incluant des enfants \u00e9pileptiques (2-18 ans), adress\u00e9s pour au moins deux dosages de la concentration plasmatique r\u00e9siduelle (C0) du VPA sur une p\u00e9riode de 13 ans.\nR\u00e9sultats : Nous avons inclus 88 enfants dont 67% (n=59) \u00e9taient en r\u00e9mission (G1) et 33% (n=29) ne r\u00e9pondaient pas aux crit\u00e8res de r\u00e9mission (G2). Dix enfants (11%) ont pr\u00e9sent\u00e9 des \u00e9v\u00e9nements ind\u00e9sirables dont les plus rapport\u00e9s \u00e9taient \u00e0 type de troubles digestifs et neuropsychologiques. La dose pond\u00e9rale (Dp) moyenne du VPA dans le G1 (21,53\u00b17,95mg\/kg\/j) \u00e9tait significativement inf\u00e9rieure \u00e0 celle du G2 (26,81\u00b19,99mg\/kg\/j), p=0,0086.\u00a0 La C0 moyenne de VPA \u00e9tait de 60,76\u00b120,22\u00b5g\/mL dans le G1 et de 62,47\u00b123,04\u00b5g\/mL dans le G2 sans diff\u00e9rence significative.\nLa Dp seuil pour la r\u00e9mission \u00e9tait de 44,44 mg\/kg\/j.\nConclusion : Dans notre \u00e9tude, la Dp moyenne du VPA des enfants \u00e9pileptiques en r\u00e9mission \u00e9tait significativement inf\u00e9rieure \u00e0 celle du G2. Un effet seuil de dose limitant l\u2019efficacit\u00e9 du traitement pour atteindre la r\u00e9mission de 44,44 mg\/kg\/j.<\/jats:p>","DOI":"10.62438\/tunismed.v103i8.5330","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T17:07:55Z","timestamp":1765904875000},"source":"Crossref","is-referenced-by-count":0,"title":["Enfant \u00e9pileptique en r\u00e9mission : Effet seuil de l\u2019acide valpro\u00efque"],"prefix":"10.62438","volume":"103","author":[{"given":"Mariem","family":"Kammoun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rim","family":"Charfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abir","family":"Boussetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khouloud","family":"Ferchichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"Affes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouna","family":"Ben Sassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syrine","family":"Ben Hammamia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouna","family":"Daldoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emna","family":"Gaies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riadh","family":"Daghfous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahar","family":"Gargah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh","family":"Trabelsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"31112","published-online":{"date-parts":[[2025,8,1]]},"container-title":["La Tunisie M\u00e9dicale"],"original-title":[],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T17:07:55Z","timestamp":1765904875000},"score":1,"resource":{"primary":{"URL":"https:\/\/latunisiemedicale.com\/index.php\/tunismed\/article\/view\/5330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":0,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.62438\/tunismed.v103i8.5330","relation":{},"ISSN":["2724-7031","0041-4131"],"issn-type":[{"value":"2724-7031","type":"electronic"},{"value":"0041-4131","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}